Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Feb 1;17(3):393-5.
doi: 10.1158/1078-0432.CCR-10-2925. Epub 2011 Jan 25.

Response to combined molecular targeting: defining the role of P-STAT3

Ann Marie Egloff  1 , Jennifer R Grandis
Affiliations
Comment

Response to combined molecular targeting: defining the role of P-STAT3

Ann Marie Egloff et al. Clin Cancer Res. .

Abstract

Src family kinase (SFK)-targeting agents are currently undergoing clinical investigation for treatment of solid malignancies. Epidermal growth factor receptor (EGFR)-independent phosphorylation of STAT3 (P-STAT3) has been identified as a mechanism of tumor resistance to agents targeting SFK. Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
EGFR- and SFK-independent activation of STAT3 provides a mechanism for Overcoming EGFR- and SFK-targeted therapies. Solid arrows indicate activation of signaling components or pathways. Dashed arrow indicates phosphorylation independent of activation. Inhibition is represented by a red T.
See this image and copyright information in PMC

Comment on

References

    1. Nagaraj NS, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin Can Res. 2010:17. - PMC - PubMed
    1. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol. 2010;6:291–9. - PMC - PubMed
    1. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, et al. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009;15:6852–61. - PMC - PubMed
    1. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res. 2009;69:1958–65. - PMC - PubMed
    1. Nagaraj NS, Smith JJ, Revetta F, Washington MK, Merchant NB. Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther. 2010;9:2322–32. - PMC - PubMed

MeSH terms